Innate Pharma Advances Lacutamab Clinical Development Program
TELLOMAK trial progresses as cohort 2 of KIR3DL2-expressing mycosis fungoides patients advances to Stage 2…
Month: February 2021
Bone Therapeutics SA: Notice of Extraordinary Shareholders’ Meeting on 26 February 2021
REGULATED INFORMATION Preliminary documents for the Extraordinary General Meeting have been made available on company’s…
Continued strong Cresemba® (isavuconazole) sales trigger milestone from Pfizer to Basilea of USD 10 million
Basel, Switzerland, February 09, 2021 Basilea Pharmaceutica Ltd. (SIX: BSLN) announced today that sales of…
Corrected Headline: RespireRx Pharmaceuticals Up Listed to OTCQB and Ticker Returns to RSPI
Glen Rock, N.J., Feb. 08, 2021 (GLOBE NEWSWIRE) — RespireRx Pharmaceuticals Inc. (OTCQB: RSPI) (“RespireRx”…
Zomedica Corp. Increases Previously Announced Bought Deal Offering of Common Shares to $173.5 Million
ANN ARBOR, Mich., Feb. 08, 2021 (GLOBE NEWSWIRE) — Zomedica Corp. (NYSE American: ZOM), (“Zomedica”…
Innate Pharma advances lacutamab clinical development program
Marseille, Feb. 09, 2021 (GLOBE NEWSWIRE) — TELLOMAK trial progresses as cohort 2 of KIR3DL2-expressing…
Nanox Announces Secondary Offering of Ordinary Shares
NEVE ILAN, Israel, Feb. 08, 2021 (GLOBE NEWSWIRE) — NANO-X IMAGING LTD (NASDAQ: NNOX) (“Nanox”…
Revive Therapeutics Files Business Acquisition Report
TORONTO, Feb. 08, 2021 (GLOBE NEWSWIRE) — Revive Therapeutics Ltd. (“Revive” or the “Company”) (CSE:RVV)…
Burning Rock Announces Preliminary Fourth Quarter and Full Year 2020 Results and Schedules Earnings Release on March 11, 2021
GUANGZHOU, China, Feb. 08, 2021 (GLOBE NEWSWIRE) — Burning Rock Biotech Limited (NASDAQ: BNR, the…
Arvinas to Present at the Guggenheim Healthcare Talks: 2021 Oncology Day
NEW HAVEN, Conn., Feb. 08, 2021 (GLOBE NEWSWIRE) — Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage…
Zomedica Corp. Announces $25.0 Million Bought Deal Offering of Common Shares
ANN ARBOR, Mich., Feb. 08, 2021 (GLOBE NEWSWIRE) — Zomedica Corp. (NYSE American: ZOM), (“Zomedica”…
Sana Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
SEATTLE, Feb. 08, 2021 (GLOBE NEWSWIRE) — Sana Biotechnology, Inc. (Nasdaq: SANA), a company focused…
Revolution Medicines Announces Closing of Upsized Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares
Underwriters’ Full Exercise of Option Brings Gross Proceeds to $300 Million REDWOOD CITY, Calif., Feb….
Organogenesis Holdings Inc. to Report Fourth Quarter and Fiscal Year 2020 Financial Results on March 16, 2021
CANTON, Mass., Feb. 08, 2021 (GLOBE NEWSWIRE) — Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading…
T2 Biosystems to Participate in the BTIG Virtual MedTech, Digital Health, Life Science & Diagnostics Tools Conference
LEXINGTON, Mass., Feb. 08, 2021 (GLOBE NEWSWIRE) — T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the…
Autolus Announces Proposed Public Offering in the United States
LONDON, Feb. 08, 2021 (GLOBE NEWSWIRE) — Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical…
Freeline Presents Data on its Gaucher Disease and Fabry Disease AAV-Based Gene Therapies at the 17th Annual WORLDSymposium™
Data demonstrate potential of FLT201 to deliver sustained levels of β-glucocerebrosidase (GCase) variant 85, a…
Atea Pharmaceuticals Announces Publication of Preclinical Data Highlighting Potent Activity of AT-527 Against SARS-CoV-2
Data underscore key mechanistic features enabling AT-527 to inhibit SARS-CoV-2 viral replication and support current…
Opiant Pharmaceuticals Announces First Patient Dosed in Confirmatory Pharmacokinetic Study Assessing OPNT003, Nasal Nalmefene, for the Treatment of Opioid Overdose
SANTA MONICA, Calif., Feb. 08, 2021 (GLOBE NEWSWIRE) — Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ: OPNT) today…
Sorrento Announces Subsidiary Company – ADNAB, Inc. – to Develop and Commercialize ADNAB™ Platform Products for Hematological Malignancies and Solid Tumors Based on an Exclusive Technology License From the Mayo Clinic
The ADNAB™ platform was developed and exclusively licensed to Sorrento by the Mayo Clinic Clinical…